Amneal Completes Kashiv BioSciences Acquisition for $375M Cash
Amneal Pharmaceuticals, Inc. announced the completion of its acquisition of Kashiv BioSciences, LLC on August 10, 2026. The transaction involved a cash payment of $375 million and the issuance of 28.9 million shares of Amneal's Class A common stock. Additionally, Kashiv sellers are eligible for up to $350 million in contingent regulatory milestone payments and 12 years of contingent royalty payments. To help finance the acquisition, Amneal LLC secured a $350 million Incremental Term Loan. This strategic acquisition aims to establish Amneal as a fully integrated global biosimilar leader, extending its growth profile into the next decade.
Key Highlights
- Acquisition of Kashiv BioSciences, LLC completed on August 10, 2026.
- Amneal paid $375,000,000 in cash for Kashiv BioSciences.
- Issued 28,942,108 shares of Class A common stock to Kashiv sellers.
- Sellers are eligible for up to $350,000,000 in contingent regulatory milestone payments.
- Sellers are eligible for 12-year contingent royalty payments based on gross profits.
- Amneal LLC secured a $350,000,000 New Incremental Term Loan from Bank of America, N.A.
- Amended the Stockholders Agreement to include new shares and update definitions.
- The acquisition establishes Amneal as a global biosimilar leader with end-to-end capabilities.
Price Impact
More from AMRX
Amneal Pharmaceuticals Acquires Kashiv BioSciences for $1.3B; Q3 Revenue $863M, Net Loss $(21.7)M
Amneal Pharmaceuticals Q3 Revenue $863M; Raises 2026 Guidance
Amneal Q2 Net Revenue $796.2M, Net Income $57.7M; New Deals Signed